PedAM

Pediatric Disease Annotations & Medicines


	proteinuria

Disease ID	706
Disease	proteinuria
Definition	The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
Synonym	[d]proteinuria [d]proteinuria (context-dependent category) [d]proteinuria (situation) [d]proteinuria nos [d]proteinuria nos (context-dependent category) [d]proteinuria nos (situation) abnormal presence of protein in urine high urine protein levels proteinuria (disorder) proteinuria (finding) proteinuria [ambiguous] proteinuria [disease/finding] proteinuria, nos proteinurias
DOID	DOID:576
UMLS	C0033687
MeSH	D011507
SNOMED-CT	SNOMEDCT_US_2016_09_01:29738008
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:146) C0020538 \| hypertension \| 94 C0022658 \| nephropathy \| 71 C0022658 \| kidney disease \| 56 C0027726 \| nephrotic syndrome \| 49 C0011847 \| diabetes \| 48 C0011881 \| diabetic nephropathy \| 42 C0022661 \| chronic kidney disease \| 35 C0035078 \| renal failure \| 30 C0017661 \| iga nephropathy \| 23 C0032914 \| preeclampsia \| 23 C0027697 \| nephritis \| 22 C0022658 \| renal disease \| 19 C0011860 \| type 2 diabetes \| 19 C0178664 \| glomerulosclerosis \| 18 C0017658 \| glomerulonephritis \| 16 C0013537 \| eclampsia \| 15 C0340274 \| gestational hypertension \| 14 C0011849 \| diabetes mellitus \| 12 C0024143 \| lupus nephritis \| 11 C0017668 \| focal segmental glomerulosclerosis \| 9 C0017665 \| membranous nephropathy \| 9 C0028754 \| obesity \| 9 C1561644 \| chronic kidney disease (ckd) \| 6 C0022660 \| acute renal failure \| 6 C0024523 \| malabsorption \| 6 C0002726 \| amyloidosis \| 6 C0178664 \| glomerular sclerosis \| 5 C0022658 \| kidney diseases \| 5 C0022658 \| renal diseases \| 5 C0002871 \| anemia \| 5 C1565489 \| renal insufficiency \| 5 C0011854 \| type 1 diabetes \| 5 C0035078 \| kidney failure \| 5 C0151650 \| renal fibrosis \| 4 C1567741 \| alport syndrome \| 4 C0019196 \| hepatitis c \| 4 C0027707 \| interstitial nephritis \| 4 C0019158 \| hepatitis \| 3 C0042870 \| vitamin d defic \| 3 C0085681 \| hyperphosphatemia \| 3 C0011881 \| diabetic kidney disease \| 3 C0022661 \| chronic renal failure \| 3 C0020538 \| hypertensive disorder \| 3 C0042870 \| vitamin d deficiency \| 3 C0027709 \| nephrocalcinosis \| 3 C0011860 \| type 2 diabetes mellitus \| 3 C0002895 \| sickle cell disease \| 3 C0020456 \| hyperglycemia \| 3 C0392525 \| nephrolithiasis \| 2 C0026764 \| myeloma \| 2 C0042373 \| vascular disease \| 2 C0011881 \| diabetic renal disease \| 2 C0020443 \| hypercholesterolemia \| 2 C0017668 \| focal glomerulosclerosis \| 2 C0042769 \| virus infection \| 2 C0019163 \| hepatitis b \| 2 C0022116 \| ischemia \| 2 C0007222 \| cardiovascular disease \| 2 C0162429 \| malnutrition \| 2 C0022661 \| end-stage renal disease \| 2 C1136085 \| monoclonal gammopathy \| 2 C0031069 \| familial mediterranean fever \| 2 C0005745 \| ptosis \| 2 C0271650 \| prediabetes \| 2 C0271051 \| macular edema \| 1 C0020538 \| systemic hypertension \| 1 C0035309 \| retinopathy \| 1 C0002986 \| fabry disease \| 1 C0011860 \| type ii diabetes \| 1 C0034152 \| henoch-schonlein purpura \| 1 C0018099 \| gout \| 1 C0020503 \| secondary hyperparathyroidism \| 1 C0009763 \| conjunctivitis \| 1 C0221239 \| rapidly progressive glomerulonephritis \| 1 C0012569 \| diplopia \| 1 C0024419 \| macroglobulinemia \| 1 C0020459 \| hyperinsulinemia \| 1 C0040034 \| thrombocytopenia \| 1 C0039730 \| thalassemia \| 1 C0403529 \| anti-gbm disease \| 1 C0034150 \| purpura \| 1 C0020538 \| vascular hypertension \| 1 C0023195 \| lcat deficiency \| 1 C0020676 \| hypothyroid \| 1 C0042384 \| vasculitis \| 1 C0020538 \| increased blood pressure \| 1 C0011860 \| diabetes mellitus type 2 \| 1 C0037315 \| sleep apnea \| 1 C0020550 \| hyperthyroidism \| 1 C0020538 \| high blood pressure \| 1 C0022679 \| cystic kidney \| 1 C0007177 \| pericardial tamponade \| 1 C0268713 \| congenital nephrotic syndrome \| 1 C0034359 \| pyuria \| 1 C0948265 \| metabolic syndrome \| 1 C0033687 \| proteinuria \| 1 C0019829 \| hodgkin's lymphoma \| 1 C0022658 \| renal disorders \| 1 C0023281 \| leishmaniasis \| 1 C0598608 \| hyperhomocysteinemia \| 1 C0036202 \| sarcoidosis \| 1 C0015624 \| fanconi syndrome \| 1 C0520679 \| obstructive sleep apnea \| 1 C0085580 \| essential hypertension \| 1 C0026764 \| multiple myeloma \| 1 C0002895 \| sickle-cell disease \| 1 C0023890 \| cirrhosis \| 1 C0085580 \| primary hypertension \| 1 C0878486 \| arteriolosclerosis \| 1 C0002871 \| anaemia \| 1 C0011644 \| scleroderma \| 1 C0021390 \| inflammatory bowel disease \| 1 C0950121 \| drash syndrome \| 1 C0403592 \| chronic allograft nephropathy \| 1 C1510471 \| hypovitaminosis \| 1 C1384514 \| primary aldosteronism \| 1 C0409974 \| lupus erythematosus \| 1 C0740394 \| hyperuricemia \| 1 C0027720 \| nephrosis \| 1 C0011854 \| type 1 diabetes mellitus \| 1 C0006142 \| breast cancer \| 1 C0020545 \| renovascular hypertension \| 1 C0022661 \| chronic kidney failure \| 1 C0024141 \| systemic lupus erythematosus \| 1 C0022661 \| chronic renal disease \| 1 C0030421 \| paraganglioma \| 1 C0024437 \| age-related macular degeneration \| 1 C0085404 \| poems syndrome \| 1 C0010346 \| crohn's disease \| 1 C0041349 \| tubulointerstitial nephritis \| 1 C0403447 \| chronic renal insufficiency \| 1 C0026470 \| monoclonal gammopathy of undetermined significance \| 1 C0029089 \| ophthalmoplegia \| 1 C0020428 \| aldosteronism \| 1 C0021831 \| bowel disease \| 1 C0024437 \| macular degeneration \| 1 C0020456 \| hyperglycaemia \| 1 C0022679 \| cystic kidneys \| 1 C0031511 \| pheochromocytoma \| 1 C0022661 \| end-stage kidney disease \| 1 C0035579 \| hypovitaminosis d \| 1 C0017665 \| membranous glomerulonephritis \| 1 C0002895 \| sickle cell anaemia \| 1 C0024299 \| lymphoma \| 1 C0002986 \| fabry's disease \| 1 C0020305 \| fetal hydrops \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:39) HLA-DRB1 \| 3123 \| CTD_human HLA-DQA1 \| 3117 \| CTD_human SOD1 \| 6647 \| CTD_human POMC \| 5443 \| CTD_human TGFB1 \| 7040 \| CTD_human IFNG \| 3458 \| CTD_human APOE \| 348 \| CTD_human MPV17 \| 4358 \| CTD_human LEP \| 3952 \| CTD_human GUSB \| 2990 \| CTD_human PPARA \| 5465 \| CTD_human AGT \| 183 \| CTD_human PTGS2 \| 5743 \| CTD_human PIGA \| 5277 \| GHR NPHS2 \| 7827 \| CLINVAR HLA-B \| 3106 \| CTD_human SPP1 \| 6696 \| CTD_human NPHS1 \| 4868 \| CLINVAR;CTD_human ALB \| 213 \| CTD_human VEGFA \| 7422 \| CTD_human PAK2 \| 5062 \| CTD_human CYBB \| 1536 \| CTD_human IL1RN \| 3557 \| CTD_human DNASE1 \| 1773 \| CTD_human CLCN5 \| 1184 \| CTD_human PAK1 \| 5058 \| CTD_human AGTR1 \| 185 \| CTD_human SCNN1A \| 6337 \| CTD_human LMX1B \| 4010 \| CTD_human REN \| 5972 \| CTD_human CTSB \| 1508 \| CTD_human DPP4 \| 1803 \| CTD_human RHOA \| 387 \| CTD_human CTSL \| 1514 \| CTD_human MUC16 \| 94025 \| CTD_human ALOX5AP \| 241 \| CTD_human HAVCR1 \| 26762 \| CTD_human NCK2 \| 8440 \| CTD_human NCK1 \| 4690 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:3) 1636 \| ACE \| infer 2944 \| GSTM1 \| infer 2952 \| GSTT1 \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:618) 55365 \| TMEM176A \| DISEASES 57554 \| LRRC7 \| DISEASES 10911 \| UTS2 \| DISEASES 3385 \| ICAM3 \| DISEASES 7132 \| TNFRSF1A \| DISEASES 9488 \| PIGB \| DISEASES 30009 \| TBX21 \| DISEASES 53405 \| CLIC5 \| DISEASES 359 \| AQP2 \| DISEASES 1071 \| CETP \| DISEASES 350 \| APOH \| DISEASES 55644 \| OSGEP \| DISEASES 7414 \| VCL \| DISEASES 23411 \| SIRT1 \| DISEASES 4282 \| MIF \| DISEASES 6948 \| TCN2 \| DISEASES 57026 \| PDXP \| DISEASES 9567 \| GTPBP1 \| DISEASES 3162 \| HMOX1 \| DISEASES 49 \| ACR \| DISEASES 4627 \| MYH9 \| DISEASES 5283 \| PIGH \| DISEASES 2158 \| F9 \| DISEASES 7076 \| TIMP1 \| DISEASES 2717 \| GLA \| DISEASES 4313 \| MMP2 \| DISEASES 4210 \| MEFV \| DISEASES 51285 \| RASL12 \| DISEASES 30844 \| EHD4 \| DISEASES 1666 \| DECR1 \| DISEASES 2936 \| GSR \| DISEASES 8797 \| TNFRSF10A \| DISEASES 2217 \| FCGRT \| DISEASES 7040 \| TGFB1 \| DISEASES 973 \| CD79A \| DISEASES 5444 \| PON1 \| DISEASES 3082 \| HGF \| DISEASES 1124 \| CHN2 \| DISEASES 5054 \| SERPINE1 \| DISEASES 56913 \| C1GALT1 \| DISEASES 727 \| C5 \| DISEASES 55848 \| PLGRKT \| DISEASES 6348 \| CCL3 \| DISEASES 4353 \| MPO \| DISEASES 1440 \| CSF3 \| DISEASES 6198 \| RPS6KB1 \| DISEASES 6347 \| CCL2 \| DISEASES 7448 \| VTN \| DISEASES 952 \| CD38 \| DISEASES 3558 \| IL2 \| DISEASES 345 \| APOC3 \| DISEASES 5829 \| PXN \| DISEASES 969 \| CD69 \| DISEASES 420 \| ART4 \| DISEASES 3458 \| IFNG \| DISEASES 2597 \| GAPDH \| DISEASES 9450 \| LY86 \| DISEASES 1839 \| HBEGF \| DISEASES 3565 \| IL4 \| DISEASES 2908 \| NR3C1 \| DISEASES 338 \| APOB \| DISEASES 5657 \| PRTN3 \| DISEASES 6402 \| SELL \| DISEASES 335 \| APOA1 \| DISEASES 7276 \| TTR \| DISEASES 8074 \| FGF23 \| DISEASES 4360 \| MRC1 \| DISEASES 847 \| CAT \| DISEASES 79809 \| TTC21B \| DISEASES 6615 \| SNAI1 \| DISEASES 1088 \| CEACAM8 \| DISEASES 3007 \| HIST1H1D \| DISEASES 3024 \| HIST1H1A \| DISEASES 2806 \| GOT2 \| DISEASES 30833 \| NT5C \| DISEASES 718 \| C3 \| DISEASES 6629 \| SNRPB2 \| DISEASES 6945 \| MLX \| DISEASES 5199 \| CFP \| DISEASES 391013 \| PLA2G2C \| DISEASES 2678 \| GGT1 \| DISEASES 968 \| CD68 \| DISEASES 1215 \| CMA1 \| DISEASES 3630 \| INS \| DISEASES 3040 \| HBA2 \| DISEASES 348 \| APOE \| DISEASES 59272 \| ACE2 \| DISEASES 81 \| ACTN4 \| DISEASES 2056 \| EPO \| DISEASES 3911 \| LAMA5 \| DISEASES 10343 \| PKDREJ \| DISEASES 50617 \| ATP6V0A4 \| DISEASES 3958 \| LGALS3 \| DISEASES 6382 \| SDC1 \| DISEASES 6737 \| TRIM21 \| DISEASES 182 \| JAG1 \| DISEASES 1401 \| CRP \| DISEASES 325 \| APCS \| DISEASES 4608 \| MYBPH \| DISEASES 284904 \| SEC14L4 \| DISEASES 271 \| AMPD2 \| DISEASES 81494 \| CFHR5 \| DISEASES 2012 \| EMP1 \| DISEASES 2694 \| GIF \| DISEASES 50640 \| PNPLA8 \| DISEASES 3891 \| KRT85 \| DISEASES 9038 \| TAAR5 \| DISEASES 2799 \| GNS \| DISEASES 3569 \| IL6 \| DISEASES 3557 \| IL1RN \| DISEASES 56886 \| UGGT1 \| DISEASES 9649 \| RALGPS1 \| DISEASES 8521 \| GCM1 \| DISEASES 440279 \| UNC13C \| DISEASES 7057 \| THBS1 \| DISEASES 54839 \| LRRC49 \| DISEASES 51187 \| RSL24D1 \| DISEASES 6519 \| SLC3A1 \| DISEASES 51196 \| PLCE1 \| DISEASES 9360 \| PPIG \| DISEASES 490 \| ATP2B1 \| DISEASES 4069 \| LYZ \| DISEASES 7450 \| VWF \| DISEASES 1182 \| CLCN3 \| DISEASES 1535 \| CYBA \| DISEASES 23495 \| TNFRSF13B \| DISEASES 949 \| SCARB1 \| DISEASES 999 \| CDH1 \| DISEASES 3340 \| NDST1 \| DISEASES 114294 \| LACTB \| DISEASES 8482 \| SEMA7A \| DISEASES 3690 \| ITGB3 \| DISEASES 5939 \| RBMS2 \| DISEASES 9172 \| MYOM2 \| DISEASES 4092 \| SMAD7 \| DISEASES 4087 \| SMAD2 \| DISEASES 3249 \| HPN \| DISEASES 5465 \| PPARA \| DISEASES 7077 \| TIMP2 \| DISEASES 25939 \| SAMHD1 \| DISEASES 5595 \| MAPK3 \| DISEASES 23523 \| CABIN1 \| DISEASES 50507 \| NOX4 \| DISEASES 3553 \| IL1B \| DISEASES 735 \| C9 \| DISEASES 1991 \| ELANE \| DISEASES 6403 \| SELP \| DISEASES 4036 \| LRP2 \| DISEASES 3791 \| KDR \| DISEASES 3931 \| LCAT \| DISEASES 4811 \| NID1 \| DISEASES 941 \| CD80 \| DISEASES 119 \| ADD2 \| DISEASES 2247 \| FGF2 \| DISEASES 1356 \| CP \| DISEASES 6774 \| STAT3 \| DISEASES 5443 \| POMC \| DISEASES 10686 \| CLDN16 \| DISEASES 118 \| ADD1 \| DISEASES 3383 \| ICAM1 \| DISEASES 950 \| SCARB2 \| DISEASES 6550 \| SLC9A3 \| DISEASES 683 \| BST1 \| DISEASES 3827 \| KNG1 \| DISEASES 51663 \| ZFR \| DISEASES 259 \| AMBP \| DISEASES 2028 \| ENPEP \| DISEASES 1950 \| EGF \| DISEASES 56302 \| TRPV5 \| DISEASES 10371 \| SEMA3A \| DISEASES 8829 \| NRP1 \| DISEASES 25824 \| PRDX5 \| DISEASES 5286 \| PIK3C2A \| DISEASES 3263 \| HPX \| DISEASES 3700 \| ITIH4 \| DISEASES 7112 \| TMPO \| DISEASES 8826 \| IQGAP1 \| DISEASES 3687 \| ITGAX \| DISEASES 54957 \| TXNL4B \| DISEASES 6687 \| SPG7 \| DISEASES 7157 \| TP53 \| DISEASES 396 \| ARHGDIA \| DISEASES 207 \| AKT1 \| DISEASES 2212 \| FCGR2A \| DISEASES 5972 \| REN \| DISEASES 5868 \| RAB5A \| DISEASES 23549 \| DNPEP \| DISEASES 185 \| AGTR1 \| DISEASES 2495 \| FTH1 \| DISEASES 10699 \| CORIN \| DISEASES 3950 \| LECT2 \| DISEASES 1956 \| EGFR \| DISEASES 2041 \| EPHA1 \| DISEASES 3439 \| IFNA1 \| DISEASES 3934 \| LCN2 \| DISEASES 4851 \| NOTCH1 \| DISEASES 3026 \| HABP2 \| DISEASES 133 \| ADM \| DISEASES 7356 \| SCGB1A1 \| DISEASES 51604 \| PIGT \| DISEASES 3606 \| IL18 \| DISEASES 5805 \| PTS \| DISEASES 5800 \| PTPRO \| DISEASES 5281 \| PIGF \| DISEASES 7082 \| TJP1 \| DISEASES 5741 \| PTH \| DISEASES 2321 \| FLT1 \| DISEASES 130271 \| PLEKHH2 \| DISEASES 22925 \| PLA2R1 \| DISEASES 8526 \| DGKE \| DISEASES 7070 \| THY1 \| DISEASES 231 \| AKR1B1 \| DISEASES 4325 \| MMP16 \| DISEASES 2040 \| STOM \| DISEASES 27163 \| NAAA \| DISEASES 6750 \| SST \| DISEASES 5468 \| PPARG \| DISEASES 3156 \| HMGCR \| DISEASES 3815 \| KIT \| DISEASES 4643 \| MYO1E \| DISEASES 4690 \| NCK1 \| DISEASES 114822 \| RHPN1 \| DISEASES 3017 \| HIST1H2BD \| DISEASES 909 \| CD1A \| DISEASES 653361 \| NCF1 \| DISEASES 54361 \| WNT4 \| DISEASES 54102 \| CLIC6 \| DISEASES 1636 \| ACE \| DISEASES 115650 \| TNFRSF13C \| DISEASES 729230 \| CCR2 \| DISEASES 1234 \| CCR5 \| DISEASES 4061 \| LY6E \| DISEASES 3046 \| HBE1 \| DISEASES 114757 \| CYGB \| DISEASES 6352 \| CCL5 \| DISEASES 58191 \| CXCL16 \| DISEASES 10630 \| PDPN \| DISEASES 7412 \| VCAM1 \| DISEASES 2215 \| FCGR3B \| DISEASES 27306 \| HPGDS \| DISEASES 2168 \| FABP1 \| DISEASES 213 \| ALB \| DISEASES 5473 \| PPBP \| DISEASES 7123 \| CLEC3B \| DISEASES 1230 \| CCR1 \| DISEASES 308 \| ANXA5 \| DISEASES 7098 \| TLR3 \| DISEASES 1437 \| CSF2 \| DISEASES 4846 \| NOS3 \| DISEASES 11244 \| ZHX1 \| DISEASES 219736 \| STOX1 \| DISEASES 5267 \| SERPINA4 \| DISEASES 81693 \| AMN \| DISEASES 3611 \| ILK \| DISEASES 7184 \| HSP90B1 \| DISEASES 26585 \| GREM1 \| DISEASES 5245 \| PHB \| DISEASES 90678 \| LRSAM1 \| DISEASES 51129 \| ANGPTL4 \| DISEASES 133418 \| EMB \| DISEASES 9839 \| ZEB2 \| DISEASES 3479 \| IGF1 \| DISEASES 5480 \| PPIC \| DISEASES 43 \| ACHE \| DISEASES 257019 \| FRMD3 \| DISEASES 1493 \| CTLA4 \| DISEASES 929 \| CD14 \| DISEASES 29071 \| C1GALT1C1 \| DISEASES 3596 \| IL13 \| DISEASES 4330 \| MN1 \| DISEASES 3627 \| CXCL10 \| DISEASES 7369 \| UMOD \| DISEASES 10465 \| PPIH \| DISEASES 624 \| BDKRB2 \| DISEASES 54205 \| CYCS \| DISEASES 10855 \| HPSE \| DISEASES 2147 \| F2 \| DISEASES 1540 \| CYLD \| DISEASES 5340 \| PLG \| DISEASES 4973 \| OLR1 \| DISEASES 1072 \| CFL1 \| DISEASES 4023 \| LPL \| DISEASES 56063 \| TMEM234 \| DISEASES 947 \| CD34 \| DISEASES 26737 \| OR1L1 \| DISEASES 27235 \| COQ2 \| DISEASES 55790 \| CSGALNACT1 \| DISEASES 836 \| CASP3 \| DISEASES 1579 \| CYP4A11 \| DISEASES 358 \| AQP1 \| DISEASES 56977 \| STOX2 \| DISEASES 9844 \| ELMO1 \| DISEASES 5319 \| PLA2G1B \| DISEASES 8639 \| AOC3 \| DISEASES 3952 \| LEP \| DISEASES 4867 \| NPHP1 \| DISEASES 4327 \| MMP19 \| DISEASES 4179 \| CD46 \| DISEASES 998 \| CDC42 \| DISEASES 285 \| ANGPT2 \| DISEASES 1909 \| EDNRA \| DISEASES 1191 \| CLU \| DISEASES 1604 \| CD55 \| DISEASES 1442 \| CSH1 \| DISEASES 147912 \| SIX5 \| DISEASES 8542 \| APOL1 \| DISEASES 9377 \| COX5A \| DISEASES 53905 \| DUOX1 \| DISEASES 28959 \| TMEM176B \| DISEASES 27319 \| BHLHE22 \| DISEASES 91662 \| NLRP12 \| DISEASES 5652 \| PRSS8 \| DISEASES 9370 \| ADIPOQ \| DISEASES 146894 \| CD300LG \| DISEASES 3321 \| IGSF3 \| DISEASES 4018 \| LPA \| DISEASES 51666 \| ASB4 \| DISEASES 3996 \| LLGL1 \| DISEASES 5345 \| SERPINF2 \| DISEASES 3039 \| HBA1 \| DISEASES 379 \| ARL4D \| DISEASES 10194 \| TSHZ1 \| DISEASES 2 \| A2M \| DISEASES 3309 \| HSPA5 \| DISEASES 1453 \| CSNK1D \| DISEASES 1585 \| CYP11B2 \| DISEASES 9622 \| KLK4 \| DISEASES 3052 \| HCCS \| DISEASES 51330 \| TNFRSF12A \| DISEASES 4843 \| NOS2 \| DISEASES 6524 \| SLC5A2 \| DISEASES 716 \| C1S \| DISEASES 29933 \| GPR132 \| DISEASES 3543 \| IGLL1 \| DISEASES 6906 \| SERPINA7 \| DISEASES 5155 \| PDGFB \| DISEASES 5069 \| PAPPA \| DISEASES 7490 \| WT1 \| DISEASES 5271 \| SERPINB8 \| DISEASES 6401 \| SELE \| DISEASES 1287 \| COL4A5 \| DISEASES 942 \| CD86 \| DISEASES 8338 \| HIST2H2AC \| DISEASES 55328 \| RNLS \| DISEASES 4088 \| SMAD3 \| DISEASES 57419 \| SLC24A3 \| DISEASES 5587 \| PRKD1 \| DISEASES 51004 \| COQ6 \| DISEASES 3043 \| HBB \| DISEASES 2152 \| F3 \| DISEASES 153571 \| C5orf38 \| DISEASES 10881 \| ACTL7A \| DISEASES 80128 \| TRIM46 \| DISEASES 3320 \| HSP90AA1 \| DISEASES 9075 \| CLDN2 \| DISEASES 8710 \| SERPINB7 \| DISEASES 114548 \| NLRP3 \| DISEASES 4842 \| NOS1 \| DISEASES 3091 \| HIF1A \| DISEASES 7430 \| EZR \| DISEASES 3266 \| ERAS \| DISEASES 857 \| CAV1 \| DISEASES 5329 \| PLAUR \| DISEASES 7100 \| TLR5 \| DISEASES 966 \| CD59 \| DISEASES 6609 \| SMPD1 \| DISEASES 7225 \| TRPC6 \| DISEASES 6614 \| SIGLEC1 \| DISEASES 5764 \| PTN \| DISEASES 4306 \| NR3C2 \| DISEASES 84639 \| IL1F10 \| DISEASES 6187 \| RPS2 \| DISEASES 1508 \| CTSB \| DISEASES 2138 \| EYA1 \| DISEASES 921 \| CD5 \| DISEASES 3146 \| HMGB1 \| DISEASES 8741 \| TNFSF13 \| DISEASES 23405 \| DICER1 \| DISEASES 5498 \| PPOX \| DISEASES 3605 \| IL17A \| DISEASES 1499 \| CTNNB1 \| DISEASES 26762 \| HAVCR1 \| DISEASES 1798 \| DPAGT1 \| DISEASES 6275 \| S100A4 \| DISEASES 5154 \| PDGFA \| DISEASES 2534 \| FYN \| DISEASES 2335 \| FN1 \| DISEASES 728 \| C5AR1 \| DISEASES 954 \| ENTPD2 \| DISEASES 4010 \| LMX1B \| DISEASES 2204 \| FCAR \| DISEASES 1785 \| DNM2 \| DISEASES 4698 \| NDUFA5 \| DISEASES 5265 \| SERPINA1 \| DISEASES 6720 \| SREBF1 \| DISEASES 3240 \| HP \| DISEASES 6288 \| SAA1 \| DISEASES 2224 \| FDPS \| DISEASES 3683 \| ITGAL \| DISEASES 60 \| ACTB \| DISEASES 23556 \| PIGN \| DISEASES 5169 \| ENPP3 \| DISEASES 337 \| APOA4 \| DISEASES 6714 \| SRC \| DISEASES 51592 \| TRIM33 \| DISEASES 2213 \| FCGR2B \| DISEASES 2526 \| FUT4 \| DISEASES 84735 \| CNDP1 \| DISEASES 9332 \| CD163 \| DISEASES 55243 \| KIRREL \| DISEASES 23607 \| CD2AP \| DISEASES 55503 \| TRPV6 \| DISEASES 4151 \| MB \| DISEASES 7037 \| TFRC \| DISEASES 6693 \| SPN \| DISEASES 84063 \| KIRREL2 \| DISEASES 4478 \| MSN \| DISEASES 5599 \| MAPK8 \| DISEASES 4311 \| MME \| DISEASES 1803 \| DPP4 \| DISEASES 54106 \| TLR9 \| DISEASES 2993 \| GYPA \| DISEASES 6721 \| SREBF2 \| DISEASES 2475 \| MTOR \| DISEASES 10724 \| MGEA5 \| DISEASES 23038 \| WDTC1 \| DISEASES 142680 \| SLC34A3 \| DISEASES 183 \| AGT \| DISEASES 22796 \| COG2 \| DISEASES 2590 \| GALNT2 \| DISEASES 5867 \| RAB4A \| DISEASES 28514 \| DLL1 \| DISEASES 1378 \| CR1 \| DISEASES 5788 \| PTPRC \| DISEASES 3075 \| CFH \| DISEASES 5743 \| PTGS2 \| DISEASES 4688 \| NCF2 \| DISEASES 7827 \| NPHS2 \| DISEASES 60676 \| PAPPA2 \| DISEASES 462 \| SERPINC1 \| DISEASES 356 \| FASLG \| DISEASES 55811 \| ADCY10 \| DISEASES 6446 \| SGK1 \| DISEASES 2214 \| FCGR3A \| DISEASES 1490 \| CTGF \| DISEASES 336 \| APOA2 \| DISEASES 962 \| CD48 \| DISEASES 57216 \| VANGL2 \| DISEASES 93183 \| PIGM \| DISEASES 912 \| CD1D \| DISEASES 10763 \| NES \| DISEASES 140576 \| S100A16 \| DISEASES 1520 \| CTSS \| DISEASES 57107 \| PDSS2 \| DISEASES 8349 \| HIST2H2BE \| DISEASES 8337 \| HIST2H2AA3 \| DISEASES 2209 \| FCGR1A \| DISEASES 10628 \| TXNIP \| DISEASES 914 \| CD2 \| DISEASES 965 \| CD58 \| DISEASES 9748 \| SLK \| DISEASES 8771 \| TNFRSF6B \| DISEASES 2334 \| AFF2 \| DISEASES 1038 \| CDR1 \| DISEASES 959 \| CD40LG \| DISEASES 653 \| BMP5 \| DISEASES 4952 \| OCRL \| DISEASES 27329 \| ANGPTL3 \| DISEASES 163782 \| KANK4 \| DISEASES 1573 \| CYP2J2 \| DISEASES 732 \| C8B \| DISEASES 5950 \| RBP4 \| DISEASES 5730 \| PTGDS \| DISEASES 186 \| AGTR2 \| DISEASES 11093 \| ADAMTS13 \| DISEASES 7422 \| VEGFA \| DISEASES 2889 \| RAPGEF1 \| DISEASES 1288 \| COL4A6 \| DISEASES 958 \| CD40 \| DISEASES 4318 \| MMP9 \| DISEASES 5476 \| CTSA \| DISEASES 5328 \| PLAU \| DISEASES 310 \| ANXA7 \| DISEASES 3633 \| INPP5B \| DISEASES 5225 \| PGC \| DISEASES 51098 \| IFT52 \| DISEASES 2022 \| ENG \| DISEASES 23051 \| ZHX3 \| DISEASES 2833 \| CXCR3 \| DISEASES 2170 \| FABP3 \| DISEASES 2934 \| GSN \| DISEASES 27293 \| SMPDL3B \| DISEASES 4153 \| MBL2 \| DISEASES 7099 \| TLR4 \| DISEASES 1043 \| CD52 \| DISEASES 240 \| ALOX5 \| DISEASES 7295 \| TXN \| DISEASES 1896 \| EDA \| DISEASES 3339 \| HSPG2 \| DISEASES 19 \| ABCA1 \| DISEASES 11326 \| VSIG4 \| DISEASES 3118 \| HLA-DQA2 \| DISEASES 1650 \| DDOST \| DISEASES 3303 \| HSPA1A \| DISEASES 1188 \| CLCNKB \| DISEASES 3055 \| HCK \| DISEASES 10673 \| TNFSF13B \| DISEASES 55937 \| APOM \| DISEASES 11330 \| CTRC \| DISEASES 1184 \| CLCN5 \| DISEASES 50943 \| FOXP3 \| DISEASES 7133 \| TNFRSF1B \| DISEASES 1041 \| CDSN \| DISEASES 4879 \| NPPB \| DISEASES 4878 \| NPPA \| DISEASES 780 \| DDR1 \| DISEASES 4524 \| MTHFR \| DISEASES 3105 \| HLA-A \| DISEASES 1471 \| CST3 \| DISEASES 7056 \| THBD \| DISEASES 1910 \| EDNRB \| DISEASES 8718 \| TNFRSF25 \| DISEASES 8029 \| CUBN \| DISEASES 6520 \| SLC3A2 \| DISEASES 10159 \| ATP6AP2 \| DISEASES 5420 \| PODXL \| DISEASES 1536 \| CYBB \| DISEASES 285440 \| CYP4V2 \| DISEASES 4868 \| NPHS1 \| DISEASES 201229 \| LYRM9 \| DISEASES 375790 \| AGRN \| DISEASES 1906 \| EDN1 \| DISEASES 54790 \| TET2 \| DISEASES 7010 \| TEK \| DISEASES 9365 \| KL \| DISEASES 795 \| S100G \| DISEASES 3440 \| IFNA2 \| DISEASES 3456 \| IFNB1 \| DISEASES 551 \| AVP \| DISEASES 5277 \| PIGA \| DISEASES 241 \| ALOX5AP \| DISEASES 150084 \| IGSF5 \| DISEASES 3030 \| HADHA \| DISEASES 51284 \| TLR7 \| DISEASES 1183 \| CLCN4 \| DISEASES 6557 \| SLC12A1 \| DISEASES 1497 \| CTNS \| DISEASES 26524 \| LATS2 \| DISEASES 6736 \| SRY \| DISEASES 2878 \| GPX3 \| DISEASES 50506 \| DUOX2 \| DISEASES 64423 \| INF2 \| DISEASES 3758 \| KCNJ1 \| DISEASES 51466 \| EVL \| DISEASES 11346 \| SYNPO \| DISEASES 3426 \| CFI \| DISEASES 6696 \| SPP1 \| DISEASES 655 \| BMP7 \| DISEASES 1285 \| COL4A3 \| DISEASES 1286 \| COL4A4 \| DISEASES 8341 \| HIST1H2BN \| DISEASES 4780 \| NFE2L2 \| DISEASES 30011 \| SH3KBP1 \| DISEASES 23365 \| ARHGEF12 \| DISEASES 10747 \| MASP2 \| DISEASES 8091 \| HMGA2 \| DISEASES 10525 \| HYOU1 \| DISEASES 5970 \| RELA \| DISEASES 9223 \| MAGI1 \| DISEASES 28996 \| HIPK2 \| DISEASES 2909 \| ARHGAP35 \| DISEASES 728441 \| GGT2 \| DISEASES 7018 \| TF \| DISEASES 1363 \| CPE \| DISEASES 255743 \| NPNT \| DISEASES 23109 \| DDN \| DISEASES 197 \| AHSG \| DISEASES 85443 \| DCLK3 \| DISEASES 25959 \| KANK2 \| DISEASES 5076 \| PAX2 \| DISEASES 200958 \| MUC20 \| DISEASES 55284 \| UBE2W \| DISEASES 960 \| CD44 \| DISEASES 7124 \| TNF \| DISEASES 387 \| RHOA \| DISEASES 6559 \| SLC12A3 \| DISEASES 400745 \| SH2D5 \| DISEASES 221981 \| THSD7A \| DISEASES 8867 \| SYNJ1 \| DISEASES 834 \| CASP1 \| DISEASES 3586 \| IL10 \| DISEASES 54872 \| PIGG \| DISEASES 721 \| C4B \| DISEASES 629 \| CFB \| DISEASES 2638 \| GC \| DISEASES 1379 \| CR1L \| DISEASES 51428 \| DDX41 \| DISEASES 284 \| ANGPT1 \| DISEASES 221223 \| CES5A \| DISEASES 100423062 \| IGLL5 \| DISEASES 84623 \| KIRREL3 \| DISEASES 930 \| CD19 \| DISEASES 3684 \| ITGAM \| DISEASES 8218 \| CLTCL1 \| DISEASES 80790 \| CMIP \| DISEASES 7421 \| VDR \| DISEASES 8972 \| MGAM \| DISEASES 1649 \| DDIT3 \| DISEASES 51499 \| TRIAP1 \| DISEASES 5228 \| PGF \| DISEASES 8742 \| TNFSF12 \| DISEASES 567 \| B2M \| DISEASES 2585 \| GALK2 \| DISEASES 344 \| APOC2 \| DISEASES 6625 \| SNRNP70 \| DISEASES 101101692 \| HELLPAR \| DISEASES 27099 \| SND1-IT1 \| DISEASES 106633808 \| SNORD143 \| DISEASES
Locus	(Waiting for update.)

Disease ID	706
Disease	proteinuria
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:124) HP:0000822 \| Hypertension \| 94 HP:0000112 \| Nephropathy \| 71 HP:0000100 \| Nephrosis \| 50 HP:0000790 \| Hematuria \| 42 HP:0012622 \| Chronic kidney disease \| 35 HP:0000083 \| Renal insufficiency \| 35 HP:0100602 \| Pre-eclampsia \| 23 HP:0000123 \| Nephritis \| 22 HP:0000096 \| Glomerulosclerosis \| 18 HP:0002907 \| Microhematuria \| 16 HP:0000099 \| Glomerular nephritis \| 16 HP:0100601 \| Eclampsia \| 15 HP:0003073 \| Hypoalbuminaemia \| 14 HP:0000097 \| focal glomerulosclerosis \| 13 HP:0000819 \| Diabetes mellitus \| 12 HP:0000969 \| Dropsy \| 11 HP:0012578 \| Membranous glomerulonephritis \| 10 HP:0001919 \| Acute renal failure \| 10 HP:0001513 \| Obesity \| 9 HP:0012594 \| High urine albumin levels \| 8 HP:0002024 \| Intestinal malabsorption \| 6 HP:0011034 \| Amyloid disease \| 6 HP:0012592 \| Albuminuria \| 6 HP:0001903 \| Anemia \| 6 HP:0003774 \| End-stage renal failure \| 5 HP:0001970 \| Interstitial nephritis \| 4 HP:0030760 \| Kidney fibrosis \| 4 HP:0100820 \| Glomerulopathy \| 4 HP:0012531 \| Pain \| 4 HP:0100512 \| Vitamin D deficiency \| 3 HP:0001941 \| acidemia \| 3 HP:0003074 \| High blood glucose \| 3 HP:0002150 \| Hypercalcinuria \| 3 HP:0000121 \| Nephrocalcinosis \| 3 HP:0012579 \| Minimal change glomerulonephritis \| 3 HP:0002905 \| Hyperphosphatemia \| 3 HP:0100520 \| Oliguria \| 3 HP:0012115 \| Liver inflammation \| 3 HP:0001945 \| Fever \| 2 HP:0012211 \| Renal functional abnormality \| 2 HP:0001824 \| Weight loss \| 2 HP:0005576 \| Renal interstitial fibrosis \| 2 HP:0000787 \| Renal calculi \| 2 HP:0012398 \| Peripheral edema \| 2 HP:0003124 \| Elevated serum cholesterol \| 2 HP:0001511 \| Prenatal onset growth retardation \| 2 HP:0004395 \| Malnutrition \| 2 HP:0003259 \| Increased serum creatinine \| 2 HP:0100806 \| Sepsis \| 2 HP:0001297 \| Cerebral vascular events \| 2 HP:0003077 \| Hyperlipidemia \| 2 HP:0100699 \| Scarring \| 2 HP:0008071 \| Maternal hypertension \| 2 HP:0000508 \| Drooping upper eyelid \| 2 HP:0001942 \| Metabolic acidosis \| 2 HP:0001541 \| Ascites \| 1 HP:0002027 \| Abdominal pain \| 1 HP:0001250 \| Seizures \| 1 HP:0003076 \| Glucosuria \| 1 HP:0100033 \| Tic disorder \| 1 HP:0000608 \| Macular degeneration \| 1 HP:0000961 \| Cyanosis \| 1 HP:0040049 \| Macular edema \| 1 HP:0000509 \| Conjunctivitis \| 1 HP:0003075 \| Hypoproteinemia \| 1 HP:0003002 \| Breast carcinoma \| 1 HP:0005110 \| Atrial fibrillation \| 1 HP:0012587 \| Gross hematuria \| 1 HP:0002900 \| Hypokalemia \| 1 HP:0000602 \| Ophthalmoplegia \| 1 HP:0100543 \| Cognitive deficits \| 1 HP:0100280 \| Morbus Crohn \| 1 HP:0012085 \| High urine neutrophil count \| 1 HP:0002668 \| Paragangliomas \| 1 HP:0002665 \| Lymphoma \| 1 HP:0002666 \| Pheochromocytoma \| 1 HP:0002664 \| Neoplasia \| 1 HP:0000651 \| Diplopia \| 1 HP:0003126 \| Tubular proteinuria \| 1 HP:0000085 \| Horseshoe kidney \| 1 HP:0002155 \| Increased triglycerides \| 1 HP:0000488 \| Noninflammatory retina disease \| 1 HP:0007957 \| Corneal clouding \| 1 HP:0030852 \| High pulse pressure \| 1 HP:0000842 \| Elevated insulin level \| 1 HP:0012189 \| Hodgkin disease \| 1 HP:0001997 \| Gout \| 1 HP:0001873 \| Low platelet count \| 1 HP:0007868 \| ARMD \| 1 HP:0002157 \| Azotaemia \| 1 HP:0000979 \| Purpura \| 1 HP:0000836 \| Overactive thyroid \| 1 HP:0007430 \| Generalized edema \| 1 HP:0001994 \| 'de toni-fanconi-debre' syndrome \| 1 HP:0001298 \| Encephalopathy \| 1 HP:0002870 \| Obstructive sleep apnea \| 1 HP:0001394 \| Hepatic cirrhosis \| 1 HP:0010741 \| Peripheral edema of lower extremity \| 1 HP:0030157 \| Flank pain \| 1 HP:0002633 \| Vasculitis \| 1 HP:0001660 \| Common arterial trunk \| 1 HP:0010535 \| Sleep apnea \| 1 HP:0001510 \| Growth deficiency \| 1 HP:0003113 \| Low blood chloride levels \| 1 HP:0002725 \| Systemic lupus erythematosus \| 1 HP:0002149 \| Hyperuricemia \| 1 HP:0000107 \| Renal cyst \| 1 HP:0030005 \| Capillary leak \| 1 HP:0002104 \| Absence of spontaneous respiration \| 1 HP:0000114 \| Proximal tubular defect \| 1 HP:0100324 \| Progressive systemic scleroderma \| 1 HP:0000076 \| Vesicoureteric reflux \| 1 HP:0011672 \| Cardiac myxoma \| 1 HP:0006775 \| Multiple myeloma \| 1 HP:0001920 \| Renal artery stenosis \| 1 HP:0002829 \| Arthralgias \| 1 HP:0000093 \| Proteinuria \| 1 HP:0003109 \| Hyperphosphaturia \| 1 HP:0100817 \| Renovascular hypertension \| 1 HP:0003158 \| Reduced urinary osmolality \| 1 HP:0008677 \| Congenital nephrosis \| 1 HP:0001410 \| Decreased liver function \| 1 HP:0030762 \| Mesangiolysis \| 1 HP:0000867 \| Secondary hyperparathyroidism \| 1

Disease ID	706
Disease	proteinuria
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:19) C0020538 \| hypertension \| 94 C0022658 \| nephropathy \| 70 C0022658 \| kidney disease \| 54 C0011881 \| diabetic nephropathy \| 42 C0035078 \| renal failure \| 30 C0027697 \| nephritis \| 22 C0017658 \| glomerulonephritis \| 16 C0022658 \| renal disease \| 13 C0268731 \| glomerular disease \| 11 C0028754 \| obesity \| 9 C0024523 \| malabsorption \| 6 C0268731 \| glomerular diseases \| 6 C0022658 \| renal diseases \| 4 C0151650 \| renal fibrosis \| 4 C1398810 \| glomerulopathy \| 4 C0020473 \| hyperlipidemia \| 2 C0020443 \| hypercholesterolemia \| 2 C0007222 \| cardiovascular disease \| 2 C0015624 \| fanconi syndrome \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:2)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs28939695	NA	4868	NPHS1	umls:C0033687	CLINVAR	NA	0.245091382	NA	NPHS1	19	35848142	C	T
rs61747728	NA	7827	NPHS2	umls:C0033687	CLINVAR	NA	0.202367032	NA	NPHS2	1	179557079	C	T

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:90)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0033687	acetaminophen	D000082	103-90-2	proteinuria	MESH:D011507	marker/mechanism	3071304
C0033687	acetylcysteine	D000111	616-91-1	proteinuria	MESH:D011507	therapeutic	17270171
C0033687	allopurinol	D000493	315-30-0	proteinuria	MESH:D011507	therapeutic	10088175
C0033687	alprazolam	D000525	28981-97-7	proteinuria	MESH:D011507	therapeutic	3622604
C0033687	amikacin	D000583	37517-28-5	proteinuria	MESH:D011507	marker/mechanism	518078
C0033687	amlodipine	D017311	88150-42-9	proteinuria	MESH:D011507	therapeutic	12484519
C0033687	atenolol	D001262	29122-68-7	proteinuria	MESH:D011507	marker/mechanism	3115369
C0033687	azithromycin	D017963	83905-01-5	proteinuria	MESH:D011507	marker/mechanism	16943303
C0033687	benazepril	C044946	86541-75-5	proteinuria	MESH:D011507	therapeutic	10515446
C0033687	bosentan	C086232	147536-97-8	proteinuria	MESH:D011507	therapeutic	8604712
C0033687	caffeine	D002110	1958/8/2	proteinuria	MESH:D011507	marker/mechanism	10803761
C0033687	carmustine	D002330	154-93-8	proteinuria	MESH:D011507	marker/mechanism	11219485
C0033687	cefmetazole	D015311	56796-20-4	proteinuria	MESH:D011507	marker/mechanism	3172294
C0033687	cefotiam	D015310	61622-34-2	proteinuria	MESH:D011507	marker/mechanism	8314287
C0033687	celecoxib	D000068579	-	proteinuria	MESH:D011507	therapeutic	19194550
C0033687	chlorthalidone	D002752	77-36-1	proteinuria	MESH:D011507	marker/mechanism	3115369
C0033687	cidofovir	C059262	113852-37-2	proteinuria	MESH:D011507	marker/mechanism	10589927
C0033687	ciprofloxacin	D002939	85721-33-1	proteinuria	MESH:D011507	marker/mechanism	9531191
C0033687	clobazam	C012255	22316-47-8	proteinuria	MESH:D011507	marker/mechanism	7624000
C0033687	clonidine	D003000	4205-90-7	proteinuria	MESH:D011507	marker/mechanism	3513563
C0033687	clozapine	D003024	5786-21-0	proteinuria	MESH:D011507	marker/mechanism	9669191
C0033687	cyclophosphamide	D003520	50-18-0	proteinuria	MESH:D011507	marker/mechanism	3270085
C0033687	cyclophosphamide	D003520	50-18-0	proteinuria	MESH:D011507	therapeutic	14563468
C0033687	cyclosporine	D016572	59865-13-3	proteinuria	MESH:D011507	marker/mechanism	11091246
C0033687	cyclosporine	D016572	59865-13-3	proteinuria	MESH:D011507	therapeutic	12169874
C0033687	deferasirox	C415250	-	proteinuria	MESH:D011507	marker/mechanism	21439361
C0033687	diatrizoate	D003973	117-96-4	proteinuria	MESH:D011507	marker/mechanism	4406739
C0033687	cisplatin	D002945	15663-27-1	proteinuria	MESH:D011507	marker/mechanism	23603837
C0033687	diclofenac	D004008	15307-86-5	proteinuria	MESH:D011507	marker/mechanism	1630997
C0033687	diltiazem	D004110	42399-41-7	proteinuria	MESH:D011507	therapeutic	2240922
C0033687	doxycycline	D004318	564-25-0	proteinuria	MESH:D011507	therapeutic	12900822
C0033687	enalapril	D004656	75847-73-3	proteinuria	MESH:D011507	marker/mechanism	14651558
C0033687	enalapril	D004656	75847-73-3	proteinuria	MESH:D011507	therapeutic	11045392
C0033687	epirubicin	D015251	56420-45-2	proteinuria	MESH:D011507	marker/mechanism	9679582
C0033687	ethambutol	D004977	74-55-5	proteinuria	MESH:D011507	marker/mechanism	15102986
C0033687	ethosuximide	D005013	77-67-8	proteinuria	MESH:D011507	marker/mechanism	623072
C0033687	everolimus	D000068338	-	proteinuria	MESH:D011507	marker/mechanism	24040781
C0033687	fenoprofen	D005279	31879-05-7	proteinuria	MESH:D011507	marker/mechanism	6375363
C0033687	fluconazole	D015725	86386-73-4	proteinuria	MESH:D011507	marker/mechanism	8442906
C0033687	folic acid	D005492	59-30-3	proteinuria	MESH:D011507	marker/mechanism	20116427
C0033687	fosinopril	D017328	98048-97-6	proteinuria	MESH:D011507	therapeutic	17803470
C0033687	ifosfamide	D007069	3778-73-2	proteinuria	MESH:D011507	marker/mechanism	11605785
C0033687	imatinib mesylate	D000068877	-	proteinuria	MESH:D011507	therapeutic	19242505
C0033687	indinavir	D019469	150378-17-9	proteinuria	MESH:D011507	marker/mechanism	9337438
C0033687	indomethacin	D007213	53-86-1	proteinuria	MESH:D011507	marker/mechanism	16943303
C0033687	indomethacin	D007213	53-86-1	proteinuria	MESH:D011507	therapeutic	11849393
C0033687	isradipine	D017275	75695-93-1	proteinuria	MESH:D011507	marker/mechanism	9176849
C0033687	ivermectin	D007559	70288-86-7	proteinuria	MESH:D011507	marker/mechanism	8555762
C0033687	lovastatin	D008148	75330-75-5	proteinuria	MESH:D011507	marker/mechanism	8225831
C0033687	masoprocol	D009637	-	proteinuria	MESH:D011507	therapeutic	19194550
C0033687	meloxicam	C065757	71125-38-7	proteinuria	MESH:D011507	marker/mechanism	17485922
C0033687	methotrexate	D008727	1959/5/2	proteinuria	MESH:D011507	marker/mechanism	12692801
C0033687	metoprolol	D008790	37350-58-6	proteinuria	MESH:D011507	marker/mechanism	3513563
C0033687	midodrine	D008879	42794-76-3	proteinuria	MESH:D011507	marker/mechanism	16520351
C0033687	minoxidil	D008914	38304-91-5	proteinuria	MESH:D011507	marker/mechanism	16645303
C0033687	nafcillin	D009254	147-52-4	proteinuria	MESH:D011507	marker/mechanism	7431606
C0033687	nicotine	D009538	-	proteinuria	MESH:D011507	marker/mechanism	20685820
C0033687	norepinephrine	D009638	51-41-2	proteinuria	MESH:D011507	marker/mechanism	464098
C0033687	olmesartan	C437965	-	proteinuria	MESH:D011507	therapeutic	18448808
C0033687	omeprazole	D009853	73590-58-6	proteinuria	MESH:D011507	marker/mechanism	7802778
C0033687	pamidronate	C019248	40391-99-9	proteinuria	MESH:D011507	marker/mechanism	19581797
C0033687	pefloxacin	D015366	70458-92-3	proteinuria	MESH:D011507	therapeutic	10946806
C0033687	phenylpropanolamine	D010665	14838-15-4	proteinuria	MESH:D011507	marker/mechanism	7109141
C0033687	phenytoin	D010672	57-41-0	proteinuria	MESH:D011507	marker/mechanism	19644425
C0033687	pirfenidone	C093844	53179-13-8	proteinuria	MESH:D011507	therapeutic	15561744
C0033687	piroxicam	D010894	36322-90-4	proteinuria	MESH:D011507	marker/mechanism	8298379
C0033687	pravastatin	D017035	81093-37-0	proteinuria	MESH:D011507	therapeutic	12105140
C0033687	propranolol	D011433	525-66-6	proteinuria	MESH:D011507	marker/mechanism	1268509
C0033687	propylthiouracil	D011441	51-52-5	proteinuria	MESH:D011507	marker/mechanism	15189700
C0033687	ramipril	D017257	87333-19-5	proteinuria	MESH:D011507	therapeutic	12631109
C0033687	rifampin	D012293	13292-46-1	proteinuria	MESH:D011507	marker/mechanism	16943303
C0033687	sirolimus	D020123	53123-88-9	proteinuria	MESH:D011507	marker/mechanism	15112032
C0033687	spironolactone	D013148	1952/1/7	proteinuria	MESH:D011507	marker/mechanism	15983956
C0033687	spironolactone	D013148	1952/1/7	proteinuria	MESH:D011507	therapeutic	18382267
C0033687	streptozocin	D013311	18883-66-4	proteinuria	MESH:D011507	marker/mechanism	11219485
C0033687	tacrolimus	D016559	109581-93-3	proteinuria	MESH:D011507	marker/mechanism	7514309
C0033687	tacrolimus	D016559	109581-93-3	proteinuria	MESH:D011507	therapeutic	1375300
C0033687	temsirolimus	C401859	-	proteinuria	MESH:D011507	marker/mechanism	19212144
C0033687	tenofovir	D000068698	-	proteinuria	MESH:D011507	marker/mechanism	15627039
C0033687	tolmetin	D014046	26171-23-3	proteinuria	MESH:D011507	marker/mechanism	6375363
C0033687	trandolapril	C052035	-	proteinuria	MESH:D011507	therapeutic	19090877
C0033687	tretinoin	D014212	302-79-4	proteinuria	MESH:D011507	therapeutic	12813006
C0033687	troglitazone	C057693	97322-87-7	proteinuria	MESH:D011507	therapeutic	11318962
C0033687	valproic acid	D014635	99-66-1	proteinuria	MESH:D011507	marker/mechanism	11891102
C0033687	valproic acid	D014635	99-66-1	proteinuria	MESH:D011507	therapeutic	23707763
C0033687	valsartan	D000068756	-	proteinuria	MESH:D011507	therapeutic	10678548
C0033687	vancomycin	D014640	1404-90-6	proteinuria	MESH:D011507	marker/mechanism	16943303
C0033687	vancomycin	D014640	1404-90-6	proteinuria	MESH:D011507	therapeutic	12680319
C0033687	vinblastine	D014747	865-21-4	proteinuria	MESH:D011507	marker/mechanism	3091246
C0033687	vitamin e	D014810	1406-18-4	proteinuria	MESH:D011507	therapeutic	19149925

FDA approved drug and dosage information(Total Drugs:24)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D011507	mevacor	lovastatin	10MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D011507	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D011507	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D011507	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D011507	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D011507	cipro	ciprofloxacin	400MG/40ML (10MG/ML)	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D011507	cipro	ciprofloxacin	250MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	No
MESH:D011507	rapamune	sirolimus	1MG/ML	SOLUTION;ORAL	Prescription	None	Yes	Yes
MESH:D011507	rapamune	sirolimus	1MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D011507	mobic	meloxicam	7.5MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D011507	mobic	meloxicam	7.5MG/5ML	SUSPENSION;ORAL	Prescription	None	Yes	Yes
MESH:D011507	gleevec	imatinib mesylate	EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE;ORAL	Discontinued	None	Yes	No
MESH:D011507	gleevec	imatinib mesylate	EQ 100MG BASE	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D011507	celebrex	celecoxib	100MG	CAPSULE;ORAL	Prescription	AB	Yes	No
MESH:D011507	celebrex	celecoxib	100MG	CAPSULE;ORAL	Prescription	None	No	No
MESH:D011507	diovan	valsartan	80MG	CAPSULE;ORAL	Discontinued	None	No	No
MESH:D011507	diovan	valsartan	80MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D011507	afinitor	everolimus	5MG	TABLET;ORAL	Prescription	None	Yes	No
MESH:D011507	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D011507	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D011507	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D011507	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D011507	torisel	temsirolimus	25MG/ML (25MG/ML)	SOLUTION;INTRAVENOUS	Prescription	None	Yes	Yes
MESH:D011507	exjade	deferasirox	125MG	TABLET, FOR SUSPENSION;ORAL	Prescription	AB	Yes	No

FDA labeling changes(Total Drugs:24)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D011507	02/14/2002	mevacor	lovastatin	Heterozygous Familial Hypercholesterolemia	New indication in adolescent boys and girls (at least one year post-menarche) 10-17 years of age	Labeling	B	-	-	-	Merck	07/17/2001	FALSE'
MESH:D011507	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D011507	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D011507	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D011507	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D011507	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D011507	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D011507	11/3/2005	rapamune	sirolimus	Prophylaxis of organ rejection in patients undergoing renal transplants	Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric (	Labeling	B	-	-	-	Wyeth	11/17/2004	FALSE'
MESH:D011507	11/3/2005	rapamune	sirolimus	Prophylaxis of organ rejection in patients undergoing renal transplants	Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric (	Labeling	B	-	-	-	Wyeth	11/17/2004	FALSE'
MESH:D011507	11/8/2005	mobic	meloxicam	Relief of signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Safety and efficacy established in patients 2 years of age and older Clinical studies evaluated doses ranging from 0.125 mg/kg/day to 0.375 mg/kg/day. There was no additional benefit demonstrated by doses above 0.125 mg/kg/day in the clinical trials. The lowest effective dose should be used Adverse events in children were similar to those in adults including skin reactions and gastrointestinal bleed risk Information on dose, PK parameters, AE profile and clinical studies	Labeling	-	-	B, P	-	Boehringer Ingelheim	04/15/2005	FALSE'
MESH:D011507	11/8/2005	mobic	meloxicam	Relief of signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis	Safety and efficacy established in patients 2 years of age and older Clinical studies evaluated doses ranging from 0.125 mg/kg/day to 0.375 mg/kg/day. There was no additional benefit demonstrated by doses above 0.125 mg/kg/day in the clinical trials. The lowest effective dose should be used Adverse events in children were similar to those in adults including skin reactions and gastrointestinal bleed risk Information on dose, PK parameters, AE profile and clinical studies	Labeling	-	-	B, P	-	Boehringer Ingelheim	04/15/2005	FALSE'
MESH:D011507	09/27/2006	gleevec	imatinib mesylate	Treatment of newly diagnosed pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase	Extended age range for the treatment of newly diagnosed CML down to pediatric patients There are no data in children < 2 years of age Follow-up in children with newly diagnosed Ph+ chronic phase CML is limited Information on hematologic toxicities, AE profile, clinical studies and dosing guidelines new for newly diagnosed pediatric patients	Labeling	-	-	B, P	-	Novartis	9/6/2006	FALSE'
MESH:D011507	09/27/2006	gleevec	imatinib mesylate	Treatment of newly diagnosed pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase	Extended age range for the treatment of newly diagnosed CML down to pediatric patients There are no data in children < 2 years of age Follow-up in children with newly diagnosed Ph+ chronic phase CML is limited Information on hematologic toxicities, AE profile, clinical studies and dosing guidelines new for newly diagnosed pediatric patients	Labeling	-	-	B, P	-	Novartis	9/6/2006	FALSE'
MESH:D011507	12/15/2006	celebrex	celecoxib	Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA)	New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs	Labeling	B	-	-	-	Pfizer	08/23/2006	FALSE'
MESH:D011507	12/15/2006	celebrex	celecoxib	Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA)	New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs	Labeling	B	-	-	-	Pfizer	08/23/2006	FALSE'
MESH:D011507	11/29/2007	diovan	valsartan	Hypertension	Labeling for 6-16 years of age Not recommended for pediatric patients less than 6 years due to safety findings possibly related to treatment or with glomerular filtration rate < 30mL/min/1.73m2 Information on dose, clinical studies in 1-16 years and pharmacokinetics No relevant differences were identified between adverse experience profile for pediatric patients and that previously reported for adult patients Information on preparation of a suspension	Labeling	B	-	-	-	Novartis	8/8/2007	FALSE'
MESH:D011507	11/29/2007	diovan	valsartan	Hypertension	Labeling for 6-16 years of age Not recommended for pediatric patients less than 6 years due to safety findings possibly related to treatment or with glomerular filtration rate < 30mL/min/1.73m2 Information on dose, clinical studies in 1-16 years and pharmacokinetics No relevant differences were identified between adverse experience profile for pediatric patients and that previously reported for adult patients Information on preparation of a suspension	Labeling	B	-	-	-	Novartis	8/8/2007	FALSE'
MESH:D011507	10/29/2010	afinitor	everolimus	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis	Approved for treatment of patients with SEGA associated with TS An open-label, single-arm safety and efficacy trial was conducted in 28 patients 3-34 years with SEGA associated with TS Afinitor has not been studied in patients with SEGA < 3 years of ageMost common adverse reactions (incidence e30%) were stomatitis, upper respiratory tract infection, sinusitis, otitis media, and pyrexiaDose reduction and/or treatment interruption may be needed to manage adverse drug reactions Information on starting dose, therapeutic drug monitoring, clinical trial, and adverse reactions New indication	Labeling	B	-	-	-	Novartis	-	FALSE'
MESH:D011507	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D011507	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D011507	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D011507	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D011507	05/30/2012	torisel	temsirolimus	Advanced recurrent/refractory solid tumors	Effectiveness in pediatric patients has not been established Torisel was studied in 59 patients 1 - 17 years and 12 patients 18 to 21 years in a phase 1-2 safety and exploratory pharmacodynamic study Adverse reactions were similar to those observedd in adults Information on dosing, clinical trials and PK parameters	Labeling	B	-	-	-	-	-	FALSE'
MESH:D011507	01/23/2013	exjade	deferasirox	Treatment of chronic iron overload in patients with non-transfusion dependent thalassemia	Approved for use in 10 years and older for NTDT Safety and effectiveness have not been established in pediatric patients less than 10 years Information on dosing, adverse reactions in adults and pediatric patients, and clinical trials New indication	Labeling	-	P	-	-	Novalar Pharmaceuticals, Inc.	-	FALSE'